TAG:
molecular diagnostic testing
Price Cuts, Long Delays in Payment Are Expected
By Joseph Burns | From the Volume XIX No. 18 – December 31, 2012 Issue
CEO SUMMARY: In addition to a steep cut in the 88305 CPT code, anatomic pathology laboratories can expect cuts in the payment from Medicare for molecular and prostate biopsy testing. Two national experts in lab billing and reimbursement warn labs to expect confusion in how both public and…
Palmetto Execs Explain Molecular Test Policies
By Joseph Burns | From the Volume XVIII No. 16 – November 28, 2011 Issue
CEO SUMMARY: To create more transparency in the process clinical labs use to submit claims for genetic tests, molecular diagnostic tests, and for laboratory-developed tests (LDT), the nation’s largest Medicare Administrative Contractor (MAC) has proposed two new local coverage determina…
Pre-authorization Coming For Pricey Molecular Tests
By Robert Michel | From the Volume XVII No. 6 – April 19, 2010 Issue
CEO SUMMARY: In response to the steep ramp-up in the utilization of genetic and molecular testing, the nation’s largest health insurers are preparing to institute new guidelines for coverage and reimbursement. These will include pre-authorization by physicians, a more effective genetic …
Lab M&A Deals in June Show Market Direction
By Robert Michel | From the Volume XVI No. 10 – July 20, 2009 Issue
CEO SUMMARY: Despite a dismal economy, the month of June spawned two interesting merger/acquisition transactions in the lab testing industry. In one case, a blood brother gobbled up a specialty diagnostics company. In another transaction, two cross-town neighbors in Kansas City m…
New Flu Strain Expected In Upcoming Flu Season
By Robert Michel | From the Volume XVI No. 10 – July 20, 2009 Issue
CEO SUMMARY: Public health labs continue to monitor for new cases of the A/Novel H1N1 flu, while preparing for what may be a difficult flu season this fall. Having coped with a 10-fold increase in testing volume, public health labs are assessing the lessons learned from the April…
CBL Path, Plus Diagnostics, Alpha Innotech, DNA Direct, Humana
By Robert Michel | From the Volume XVI No. 9 – June 29, 2009 Issue
NEW PATHOLOGY LABS OPEN ON EAST COAST TIMES MUST BE GOOD for anatomic pathology companies—at least two companies have each announced the opening of a new laboratory facility. On the East Coast, it was CBL Path, Inc., of Rye Brook, New York, which expanded. On May 29, it a…
Molecular Diagnostics: How Beaumont Built A Successful Program
By Robert Michel | From the Volume XII No. 11 – August 1, 2005 Issue
CEO SUMMARY: It was about 15 years ago when William Beaumont Hospital and Beaumont Reference Laboratories first began offering molecular diagnostic testing services to clinicians. This successful effort came about because of effective strategic planning, use of consulting expertise at key…
LIS Market Evolving To Serve New Needs
By Robert Michel | From the Volume XII No. 8 – May 30, 2005 Issue
CEO SUMMARY: Ongoing reimbursement declines, coupled with other key factors, are pushing labs to seek new capabilities for their laboratory information systems (LIS). Another influence is the growth of molecular diagnostic programs in hospital labs. Molecular testing places unique demands…
“State of Industry” Report On Molecular Diagnostics
By Robert Michel | From the Volume X No. 10 – July 28, 2003 Issue
CEO SUMMARY: Enterprise Analysis Corporation has launched an ambitious survey that will include 150 laboratories performing molecular testing in the United States. Last week it released information about the first 51 labs contacted in this effort. The survey provides an intriguing look at…
LabCorp’s MacMahon Provides Insights About Lab Marketplace
By Robert Michel | From the Volume X No. 5 – April 14, 2003 Issue
CEO SUMMARY: Pathologists will be particularly interested in what Thomas MacMahon has to say about the evolution of laboratory medicine. As Chairman, President, and CEO of Laboratory Corporation of America Holdings, he has continuous access to some of the best strategic analysis about the…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized